Comparison of Chronic Angioscopic Findings of Bare Metal Stents, 1st-Generation Drug-Eluting Stents and 2nd-Generation Drug-Eluting Stents　- Multicenter Study of Intra-Coronary Angioscopy After Stent (MICASA).

BACKGROUND No previous study has reported a comprehensive comparison of the chronic angioscopic findings after bare metal stent (BMS), and 1st- and 2nd-generation drug-eluting stents (DES). METHODSANDRESULTS The Multicenter Study on Intra-Coronary Angioscopy after Stent (MICASA) is a multicenter registry of coronary angioscopy. A total of 264 stents were observed by coronary angioscopy 1 year after PCI. There were 15 BMS, 90 1st-generation DES, and 159 2nd-generation DES. Neointimal coverage (NC) of the stent was classified into 4 grades from 0 (no coverage) to 3 (complete coverage). Yellow color (YC) of plaque at the stented segment was graded from 0 (white) to 3 (bright yellow). Minimum (Min-) and Maximum (Max-) NC grade were significantly lower with 1st- and 2nd-generation DES than with BMS. Although the Max-NC grade was similar, the Min-NC grade was significantly higher for 2nd-generation DES than for 1st-generation DES. Both the YC grade and the incidence of thrombus with 2nd-generation DES were lower than with the 1st-generation DES and were comparable to BMS. Multivariate analysis showed that low-density lipoprotein, 1st-generation DES, and acute coronary syndrome were independent factors for yellow plaque (YG2 or 3), and that hypertension and 1st-generation DES were independent factors for the incidence of thrombus. CONCLUSIONS Coronary angioscopy revealed more homogeneous coverage with white neointima and less thrombus after 2nd-generation DES as compared with 1st-generation DES. These findings may explain the favorable clinical outcomes observed for patients treated with 2nd-generation DES. (Circ J 2016; 80: 1916-1921).

[1]  Y. Jang,et al.  Favorable neointimal coverage in everolimus-eluting stent at 9 months after stent implantation: comparison with sirolimus-eluting stent using optical coherence tomography , 2010, The International Journal of Cardiovascular Imaging.

[2]  P. Serruys,et al.  The 'Ermenonville' classification of observations at coronary angioscopy--evaluation of intra- and inter-observer agreement. European Working Group on Coronary Angioscopy. , 1994, European heart journal.

[3]  K. Kodama,et al.  Atherosclerotic change at one year after implantation of Endeavor zotarolimus-eluting stent vs. everolimus-eluting stent. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[4]  A. Kastrati,et al.  Everolimus-Eluting Versus Sirolimus-Eluting Stents: A Meta-Analysis of Randomized Trials , 2011, Circulation. Cardiovascular interventions.

[5]  G. Stone,et al.  Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. , 2015, Journal of the American College of Cardiology.

[6]  G. Stone,et al.  Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis , 2012, The Lancet.

[7]  M. Nishino,et al.  Difference of neointimal formational pattern and incidence of thrombus formation among 3 kinds of stents: an angioscopic study. , 2010, JACC. Cardiovascular interventions.

[8]  M. Hori,et al.  Serial Angioscopic Evidence of Incomplete Neointimal Coverage After Sirolimus-Eluting Stent Implantation: Comparison With Bare-Metal Stents , 2007, Circulation.

[9]  Masataka Nakano,et al.  The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. , 2011, Journal of the American College of Cardiology.

[10]  Samin K. Sharma,et al.  Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. , 2011, Journal of the American College of Cardiology.

[11]  C. Vrints,et al.  Stent thrombosis with drug-eluting and bare-metal stents , 2012, The Lancet.

[12]  K. Hirata,et al.  Neoatherosclerosis and mural thrombus detection after sirolimus-eluting stent implantation. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[13]  Seung‐Jung Park,et al.  Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials , 2012, Clinical Research in Cardiology.

[14]  P. Serruys,et al.  Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents: A Prospective Cohort Study , 2012, Circulation.

[15]  Coronary angioscopic findings 9 months after everolimus-eluting stent implantation compared with sirolimus-eluting stents. , 2013, Journal of cardiology.

[16]  Michael Joner,et al.  Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. , 2013, JACC. Cardiovascular interventions.

[17]  R. Virmani,et al.  Pathology of Second-Generation Everolimus-Eluting Stents Versus First-Generation Sirolimus- and Paclitaxel-Eluting Stents in Humans , 2014, Circulation.

[18]  S. Hahn,et al.  'Real world' comparison of drug-eluting stents vs bare metal stents in the treatment of unselected patients with acute ST-segment elevation myocardial infarction. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[19]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[20]  Patrick W Serruys,et al.  Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy , 2004, The Lancet.

[21]  Coronary angioscopic findings eight months after sirolimus-eluting stent implantation: a comparison between ST-elevation myocardial infarction and stable angina pectoris. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[22]  P. Serruys,et al.  Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. , 2012, European heart journal.

[23]  Neville Kukreja,et al.  Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.

[24]  Ousa,et al.  A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .

[25]  R. Virmani,et al.  Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization , 2007, Circulation.